Differences in Disease Severity but Similar Telomere Lengths in Genetic Subgroups of Patients with Telomerase and Shelterin Mutations
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The bone marrow failure syndrome dyskeratosis congenita (DC) has been considered to be a disorder of telomere maintenance in which disease features arise due to accelerated shortening of telomeres. By screening core components of the telomerase and shelterin complexes in patients with DC and related bone marrow failure syndromes we have identified 24 novel mutations: 11 in the RNA component of telomerase (TERC), 8 in the reverse transcriptase component (TERT), 4 in dyskerin (DKC1) and 1 in TRF1-interacting nuclear factor 2 (TINF2). This has prompted us to review these genetic subtypes in terms of telomere length, telomerase activity and clinical presentation among 194 genetically characterised index cases recruited onto the registry in London. While those with DKC1 and TINF2 mutations present at a younger age and have more disease features than those with TERC or TERT mutations, there is no difference in telomere length between these groups. There is no difference in the age of onset and numbers of disease features seen in those with TERC and TERT mutations despite the fact that the latter show higher levels of telomerase activity in vitro. The incidence of aplastic anaemia is greater in patients with TERC or TINF2 mutations compared to patients with DKC1 mutations, and cancer incidence is highest in patients with TERC mutations. These data are the first to provide robust comparisons between different genetic subtypes of telomerase and shelterin mutations (the "telomereopathies") and clearly demonstrate that disease severity is not explained by telomere length alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Because of the end-replication problem [3] telomeres shorten with each cell division and when they become critically short, a p53-dependent checkpoint is activated that leads to apoptosis or cell senescence [4–6].”
BackgroundShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 1×
“Other patients may present with only aplastic anaemia (AA) [29,30], myelodysplastic syndrome (MDS) [31,32], acute myeloid leukaemia (AML) [33] pulmonary fibrosis [34,35] and liver fibrosis [36], and collectively these can be referred to as the ‘telomereopathies’.”
BackgroundEvidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age.
Vaziri, H., Dragowska, W., Allsopp, R. C., Thomas, T. E., Harley, C. B., & Lansdorp, P. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9857 · Cited by 1,132 · cited 1×
“Because of the end-replication problem [3] telomeres shorten with each cell division and when they become critically short, a p53-dependent checkpoint is activated that leads to apoptosis or cell senescence [4–6].”
BackgroundHeiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., Poustka, A., & Dokal, I. (1998) · Nature Genetics · doi:10.1038/ng0598-32 · Cited by 976 · cited 3×
“None have been reported previously and none are reported among previous screens of normal healthy individuals [15,16,20,30] or on dbSNP or the 1000 genomes database.”
BackgroundSelf-citationThe RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita
Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P. J., & Dokal, I. (2001) · Nature · doi:10.1038/35096585 · Cited by 960 · cited 2×
“Telomere terminal restriction fragment lengths were determined by Southern blot analysis using the sub-telomeric probe pTelBam8 in DNA extracted from total peripheral blood white cells, as previously described [16].”
BackgroundMethodSelf-citationAdult-onset pulmonary fibrosis caused by mutations in telomerase
Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., & Garcia, C. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701009104 · Cited by 894 · cited 1×
“Other patients may present with only aplastic anaemia (AA) [29,30], myelodysplastic syndrome (MDS) [31,32], acute myeloid leukaemia (AML) [33] pulmonary fibrosis [34,35] and liver fibrosis [36], and collectively these can be referred to as the ‘telomereopathies’.”
BackgroundTelomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823 · cited 1×
“Telomere shortening has therefore been linked to the processes of both aging [8] and cancer [9].”
BackgroundLinking functional decline of telomeres, mitochondria and stem cells during ageing
Sahin, E., & DePinho, R. A. (2010) · Nature · doi:10.1038/nature08982 · Cited by 759 · cited 1×
“Telomere shortening has therefore been linked to the processes of both aging [8] and cancer [9].”
BackgroundMutations in TERT, the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia
Yamaguchi, H., Calado, R. T., Ly, H., Kajigaya, S., Baerlocher, G. M., Chanock, S. J., Lansdorp, P. M., & Young, N. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042980 · Cited by 723
Protein Composition of Catalytically Active Human Telomerase from Immortal Cells
Cohen, S. B., Graham, M. E., Lovrecz, G. O., Bache, N., Robinson, P. J., & Reddel, R. R. (2007) · Science · doi:10.1126/science.1138596 · Cited by 669 · cited 1×
“The four most common genetic subtypes of DC are those that involve either the core components of the telomerase complex [23], the RNA (TERC), the reverse transcriptase (TERT) and the accessory protein dyskerin (DKC1), or the shelterin component, the telomeric repeat binding factor 1-interacting nuclear factor 2 (TINF2…”
BackgroundDyskeratosis congenita in all its forms
Dokal, I. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02109.x · Cited by 575
Self-citationTIN2, a new regulator of telomere length in human cells
Kim, S.-H., Kaminker, P., & Campisi, J. (1999) · Nature Genetics · doi:10.1038/70508 · Cited by 525 · cited 1×
“protein (snoRNP) complexes [44], predominantly involved in ribosomal RNA processing [45], as well as a core component of telomerase; and (iii) the predominantly de novo mutations in TINF2, encoding a core component of the telomere-binding protein complex, shelterin [46,47].”
BackgroundCancer in dyskeratosis congenita
Alter, B. P., Giri, N., Savage, S. A., & Rosenberg, P. S. (2009) · Blood · doi:10.1182/blood-2008-12-192880 · Cited by 478
Vulliamy, T., Marrone, A., Szydlo, R., Walne, A., Mason, P. J., & Dokal, I. (2004) · Nature Genetics · doi:10.1038/ng1346 · Cited by 461 · cited 1×
“disease anticipation associated with telomere shortening in families with TERC and TERT mutations [17,40,41], shorter telomeres among patients with TINF2 mutations [42], and patients with severe disease caused by DKC1 mutations having shorter telomeres than those with mild disease [43].”
BackgroundSelf-citationArmanios, M., Chen, J.-L., Chang, Y.-P. C., Brodsky, R. A., Hawkins, A., Griffin, C. A., Eshleman, J. R., Cohen, A. R., Chakravarti, A., Hamosh, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508124102 · Cited by 452 · cited 1×
“disease anticipation associated with telomere shortening in families with TERC and TERT mutations [17,40,41], shorter telomeres among patients with TINF2 mutations [42], and patients with severe disease caused by DKC1 mutations having shorter telomeres than those with mild disease [43].”
BackgroundTelomeres, telomerase, and aging: Origin of the theory
Olovnikov, A. M. (1996) · Experimental Gerontology · doi:10.1016/0531-5565(96)00005-8 · Cited by 431
Savage, S. A., Giri, N., Baerlocher, G. M., Orr, N., Lansdorp, P. M., & Alter, B. P. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.10.004 · Cited by 414 · cited 1×
“None have been reported previously and none are reported among previous screens of normal healthy individuals [15,16,20,30] or on dbSNP or the 1000 genomes database.”
BackgroundTelomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations
Diaz de Leon, A., Cronkhite, J. T., Katzenstein, A.-L. A., Godwin, J. D., Raghu, G., Glazer, C. S., Rosenblatt, R. L., Girod, C. E., Garrity, E. R., Xing, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010680 · Cited by 377
Alter, B. P., Baerlocher, G. M., Savage, S. A., Chanock, S. J., Weksler, B. B., Willner, J. P., Peters, J. A., Giri, N., & Lansdorp, P. M. (2007) · Blood · doi:10.1182/blood-2007-02-075598 · Cited by 356 · cited 1×
“It is not surprising therefore that DC has been considered to represent the clinical manifestation of defective telomere maintenance and indeed, very short telomeres are a hallmark of this disease [24–26].”
BackgroundVulliamy, T., Beswick, R., Kirwan, M., Marrone, A., Digweed, M., Walne, A., & Dokal, I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800042105 · Cited by 334 · cited 1×
“Eight disease genes (DKC1, TERC, TERT, NOP10, NHP2, TINF2, C16orf57 and TCAB1) have been identified to date [15–22] and all but one are known to be involved in telomere maintenance.”
BackgroundSelf-citationWalne, A. J., Vulliamy, T., Beswick, R., Kirwan, M., & Dokal, I. (2008) · Blood · doi:10.1182/blood-2008-05-153445 · Cited by 317 · cited 2×
“From this same group of patients we have previously reported on 4 families with MDS/AML and mutations in TERC or TERT [53], as well as 33 families with mutations in the TINF2 gene [39,42] and have also identified 14 families with recurrent DKC1 mutations and 3 families with recurrent TERC mutations.”
BackgroundResultSelf-citationSyndromes of Telomere Shortening
Armanios, M. (2009) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082908-150046 · Cited by 317
Walne, A. J., Vulliamy, T., Marrone, A., Beswick, R., Kirwan, M., Masunari, Y., Al-Qurashi, F.-H., Aljurf, M., & Dokal, I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm111 · Cited by 316 · cited 1×
“Eight disease genes (DKC1, TERC, TERT, NOP10, NHP2, TINF2, C16orf57 and TCAB1) have been identified to date [15–22] and all but one are known to be involved in telomere maintenance.”
BackgroundSelf-citationMutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome
Yamaguchi, H., Baerlocher, G. M., Lansdorp, P. M., Chanock, S. J., Nunez, O., Sloand, E., & Young, N. S. (2003) · Blood · doi:10.1182/blood-2003-01-0335 · Cited by 301 · cited 5×
“From this same group of patients we have previously reported on 4 families with MDS/AML and mutations in TERC or TERT [53], as well as 33 families with mutations in the TINF2 gene [39,42] and have also identified 14 families with recurrent DKC1 mutations and 3 families with recurrent TERC mutations.”
BackgroundInfluentialDisruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita
Zhong, F., Savage, S. A., Shkreli, M., Giri, N., Jessop, L., Myers, T., Chen, R., Alter, B. P., & Artandi, S. E. (2011) · Genes & Development · doi:10.1101/gad.2006411 · Cited by 262
Telomere length in leukocyte subpopulations of patients with aplastic anemia
Brümmendorf, T. H., Maciejewski, J. P., Mak, J., Young, N. S., & Lansdorp, P. M. (2001) · Blood · doi:10.1182/blood.v97.4.895 · Cited by 233
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia
Calado, R. T., Regal, J. A., Hills, M., Yewdell, W. T., Dalmazzo, L. F., Zago, M. A., Lansdorp, P. M., Hogge, D., Chanock, S. J., Estey, E. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807057106 · Cited by 184 · cited 2×
“From this same group of patients we have previously reported on 4 families with MDS/AML and mutations in TERC or TERT [53], as well as 33 families with mutations in the TINF2 gene [39,42] and have also identified 14 families with recurrent DKC1 mutations and 3 families with recurrent TERC mutations.”
BackgroundDu, H.-Y., Pumbo, E., Ivanovich, J., An, P., Maziarz, R. T., Reiss, U. M., Chirnomas, D., Shimamura, A., Vlachos, A., Lipton, J. M., et al. (2009) · Blood · doi:10.1182/blood-2008-07-166421 · Cited by 158 · cited 1×
“No equivalent comparison has been made previously although a trend toward higher residual TRAP activity of TERT mutations has been apparent in other studies [26,30,32].”
ResultKirwan, M., Vulliamy, T., Marrone, A., Walne, A. J., Beswick, R., Hillmen, P., Kelly, R., Stewart, A., Bowen, D., Schonland, S. O., et al. (2009) · Human Mutation · doi:10.1002/humu.21115 · Cited by 109 · cited 2×
“Telomerase repeat amplification protocol (TRAP) assay The TRAP assay was performed as previously described [53].”
MethodResultSelf-citation
Cited by
Danazol Treatment for Telomere Diseases
Townsley, D. M., Dumitriu, B., Liu, D., Biancotto, A., Weinstein, B., Chen, C., Hardy, N., Mihalek, A. D., Lingala, S., Kim, Y. J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515319 · Cited by 415
Bone marrow failure and the telomeropathies
Townsley, D. M., Dumitriu, B., & Young, N. S. (2014) · Blood · doi:10.1182/blood-2014-05-526285 · Cited by 291
Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization
Lim, C. J., & Cech, T. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00328-y · Cited by 273
TERC promotes cellular inflammatory response independent of telomerase
Liu, H., Yang, Y., Ge, Y., Liu, J., & Zhao, Y. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz584 · Cited by 88
Beier, F., Foronda, M., Martinez, P., & Blasco, M. A. (2012) · Blood · doi:10.1182/blood-2012-03-418038 · Cited by 79
Metadata
- Authors
- Vulliamy, T. J., Kirwan, M. J., Beswick, R., Hossain, U., Baqai, C., Ratcliffe, A., Marsh, J., Walne, A., & Dokal, I.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-09-13
- Volume
- 6
- Issue
- 9
- Pages
- e24383
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2021391040
- Cited by
- 105
- References
- 30
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.